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Abstract
Purpose Adherence to growth hormone (GH) treatment impacts clinical outcomes. The aim of this study is to assess the
impact of adherence to rhGH treatment (2 years) on auxological outcomes.
Methods Multicentric, retrospective observational study in rhGH-naïve GHD/SGA children treated with Saizen® during ≥2
years. Growth response was assessed by evaluating the change in height standard deviation score (ΔH SDS) and the index of
responsiveness (IoR). Adherence was monitored using EasyPod™ Connect device.
Results A total of 110 patients (3 Spanish centers) were evaluable (GHD n= 76, SGA n= 34). Adherence was 95.6 and
93.9% (year 1, 2). SGA and GHD children showed an increase of 0.6 cm/year and 1.1 cm/year for each 10% adherence
modification. Lower adherence was observed in patients with lower pretreatment height velocity (HV) and in patients whose
parents had a lower level of education. A positive correlation between index of responsiveness (IoR) during the first and
second years with HV SDS during the second year and between IoR2 and adherence (year 1, 2) was observed. The
frequency of patients with HV > 1 SD was higher (p= 0.025) among patients with adherence >90%. The best model to
predict the height gain(cm) reaching an adjusted R squared of 0.489 involved percentage of adherence, Tanner stage,
pretreatment HV, dose of rhGH, and whether the treatment was initiated before or after puberty.
Conclusions Adherence during the first 2 years of response was very high >90% and showed a negative association with
age, pretreatment HV and treatment duration and a positive correlation with the level of parent education.
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Growth response is considered to be highly variable. Dif-
ferent prediction models have showed age at start, treatment
duration, and dose of growth hormone (GH) as predictive
factors of growth response. Adherence to treatment has an
important effect on growth in patients receiving recombi-
nant human growth hormone (rhGH). However, none of the
prediction models included adherence into their models,
because it is very difficult to assess adherence accurately
[1, 2].
The main goal of the rhGH treatment, in small for
gestational age (SGA) and growth hormone deficiency
(GHD) patients with reduced height, is to allow patients to
quickly attain compensatory growth, eventually reaching
the target height (TH) standard deviation score (SDS), fol-
lowed by a maintenance phase, a proper pubertal height
gain, and an adult height close to their TH [3].
According to the World Health Organization, adherence
to treatment is a worldwide problem [4, 5]. Previous studies
have demonstrated the importance of adherence in rhGH
treatment [6, 7], although the adherence assessment used
proved somewhat unreliable. For instance, the use of
nonelectronic rhGH injection devices makes it highly dif-
ficult to obtain an objective assessment of compliance.
Moreover, the significant variability in methods of detection
and definitions of adherence utilized in studies must also be
considered [8]. Newly available electronic or automatic
administering devices are quickly becoming a highly useful
tool in monitoring adherence to rhGH treatment [9].
Adherence data for patients using the EasyPodTM electronic
device are both more accurate and easier to obtain than
pharmacy dispensing data. These developments facilitate
the early detection of suboptimal compliance to treatment,
allowing these problems to be corrected as soon as they
occur [9].
Several studies have attempted to design predictive
models for treatment responses to rhGH by combining
diverse auxological and biochemical variables [10–12].
However, while these studies have had varying degrees of
success, very few have considered how adherence to rhGH
affects the desired clinical outcome [2], despite the common
knowledge that compliance is frequently suboptimal. Fur-
thermore, potentially modifiable factors associated with
pediatric nonadherence to rhGH treatment is also been
looked for [13].
In the recent Spanish DATAC study, the height velocity
(HV) SDS after 1-year treatment with rhGH was explained
(R2= 0.511) as a function of the TH, the bone age (BA)
delay, the pretreatment HV, and the adult height prognosis
[10]. However, in this study, adherence to the rhGH treat-
ment was not considered. Another example may be
observed in the EasyPod™ Connect Observational Study
(ECOS), where the long-term outcomes of rhGH therapy
(Easypod™ electronic device) in rhGH-naïve pediatric
subjects from 24 national studies were assessed. This study
described the high compliance rates of patients with Saizen®
[8], but it was not specifically designed to determine the
impact of adherence to the rhGH treatment on clinical
outcomes. Therefore, it is necessary to assess the impor-
tance of optimal vs. suboptimal adherence by studying its
impact on auxological outcomes, such as HV and
height gain.
The correlation between a high adherence rate and an
optimal clinical response during the first year of rhGH
treatment was consistently reported [6, 14]. However, this
relation might be influenced by the intensity of the catch-up
effect during the first year of treatment.
Furthermore, a decrease in adherence after the first year
of rhGH treatment was reported [14]. Adherence became
less important to subjects as the height SDS approached the
TH SDS during the compensatory growth phase, before
entering the maintenance growth phase in which the HV is
normal.
Therefore, extending the assessment of adherence and its
relevance until the second year (continuing through the
compensatory growth phase) would allow for a better
definition of the trade-off between rhGH treatment and
clinical outcomes. This extension would also contribute to
identifying a higher proportion of less adherent patients,
allowing for the development of a more reliable growth
predictive model.
The primary objective of this study is to assess the
possible relationship between adherence to rhGH treatment
and clinical response (HV and height gain) after 1 and 2
years of treatment. The secondary endpoints included the
identification of factors that may affect adherence and,
consequently, treatment outcomes.
Methods
This is a multicentric non-interventional, retrospective
observational study. Patients were recruited between Feb-
ruary and November 2018. (competitive recruitment) by the
pediatric endocrinologists of three Spanish centres: Hospital
Miguel Servet (Zaragoza), Consorcio Hospital General
Universitario (Valencia) and Hospital de Donosti (San
Sebastian).
The patients included were all rhGH-naïve children (≤18
years) with idiopathic GHD and SGA diagnosis who had
been treated with rhGH (Saizen®) for at least 2 years, with a
treatment onset date starting in or after October 2014.
Adherence to treatment must have been monitored with
EasyPodTM device with Connect platform. Syndromic
patients or those with some associated pathology
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(chromosomopathies, severe inherited cardiomyopathy,
severe enterocolitis, brain paralysis, or undergoing cancer
treatment) were excluded from the study. Patients or legal
guardians were required to sign the informed consent form
in order to participate in the study.
Patient data were retrospectively collected by investiga-
tors involved in the clinical side of the study in an electronic
Case Report Form over the 2-year period. The data col-
lected included:
(1) clinical history (parents’ height [cm and SDS], parents’
level of education, gestational age [weeks] and weight [kg and
SDS] and height [cm and SDS] at birth); (2) demographic and
anthropometric characteristics (age [years], sex, weight [kg
and SDS], height [cm and SDS], HV [cm/years and SDS], TH
[mother’s height+ father’s height)/2 ± 6.5 cm, [15], cm and
SDS]; height gain [height SDS, calculated according to
Spanish standards [16] with height references for healthy
Spanish children [17]; Tanner scale scores [18, 19], BA
(years) and height prognosis according to Bayley and Pinneau
method [20] [cm and SDS]), (3) clinical and treatment char-
acteristics (dose of GH [mg], treatment indication [GHD or
SGA] and maximum level of GH [ng/ml], and adverse events
[AEs, summarized presenting the number of events, the
number of subjects, and percentage]), (4) laboratory para-
meters (efficacy assessments; insulin-like growth factor-1
(IGF-1) levels [ng/ml], IGF-BP3 [mcg/ml]and maximum GH
peak [ng/ml]), and (5) reported adherence (percentage of daily
adherence recorded by the injection device [EasyPodTM
device with Connect platform]: number of injections received
divided by the number of prescribed injections multiplied by
100, during the period of the study [1 or 2 years]). Informa-
tion was obtained at start treatment (treatment prescription)
and from each yearly visit (1 and 2 years after start treatment).
Parents educational level was included (none, primary edu-
cation, secondary education, pre university, formative cycle,
university, post-grade).
Study size
The sample size required was determined by a two-tailed
significance of 5, 80% power, and an assumed 1.5 popu-
lation standard variation, considering that data were
incomplete for up to 10% of patients; it was 100 subjects.
Statistical methods
The statistical study was carried out jointly and separating
(GDH and SGA) although the results obtained have been
very similar. This is because the results regarding growth
are similar during the first 2 years.
Patients were classified as GHD or SGA for subgroup
analyses. The adherence analysis included two pre-
established categories of adherence: optimal (≥85%) and
suboptimal (<85%) according the number of doses received
in relation to the number of doses programmed [8].
Responses to the rhGH treatment in the first 2 years were
measured in terms of: (1) change in height SDS (Δ HSDS) in
the first and second year, as well as in both years combined,
and (2) index of responsiveness (IoR) [21], a parameter that
compares the observed first year HV to a predicted HV
derived from prediction models [22], in the first and second
year, where: IoR1= (HV first year− [12.41− 0.36 × age at
start GH+ 0.47 × birth weight SDS+ 1.54 × (log[3 × GH
dose at start GH (mg/kg/week)])− 0.6 × [HSDS 1 year− TH
SDS]+ 0.28 × weight SDS 1 year)/1.72; and IoR2= (HV
second year− [5.69− 0.09 × age at start GH+ 0.63 × (log
[3 × GH dose at start GH(mg/kg/wk)])+ 0.24 × weight SDS 2
year+ 0.31 ×HV first year)/1.19.
Height gain > 0.3 SDS, >0.5 SDS, or HV > 1 SDS or Δ
HV > 3 cm/year during the first year were evaluated for
analyzing the good response factors in the first year [23].
The association between the continuous measure of
adherence at the 2-year point and clinical continuous or
discrete parameters was analyzed based on a correlation
analysis using the Pearson and Spearman methods.
The comparison between adherence after 2 years (≥85%
vs. <85%) with categorical clinical parameters (yes/no) was
evaluated using the Chi-squared test. Only three patients
went from Tanner stage 1–2 and one patient from 2 to 3, so
no differential study of their growth has been carried out.
The asymptomatic method was applied to estimate the
95% confidence interval (CI). The comparison between
adherence (2 years) and clinical continuous and discrete
parameters, as well as the comparison between clinical
parameters (yes/no) and the continuous measure of adher-
ence, were later subjected to the Mann–Whitney U test and
the T-test. Satterthwaite approximation was used in the T-
test if unequal variances were stated based on the F-test.
Two-sided P values were obtained and statistically sig-
nificant results were declared if p < 0.05. The 95% CI for
the mean difference was based on an asymptotic method.
The 95% CI for the median difference was based on the
Hodges–Lehmann method.
Predictive models for the HV and height gain (SDS) as
well as dependent variables (based on multiple regression
model adjusted by potential prognostic variables [weight and
size at birth, sex, TH, parents educational level, maximum
level of GH, IGF-1, and IGF-BP3 levels, age at start of
therapy, pubertal stage, BA, pretreatment, first and second
year HV, rhGH dose, TH, weight, height, adherence…])
were generated using general linear models. Bonferroni
multiple test has been used for multiple comparison.
Prognostic analyses were performed after a backward
stepwise selection of factors in the complete model. The
selection criterion was based on adjusted R2, also taking
into account the sample size and the number of parameters
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established within the model. The model with the highest
adjusted R2 was selected. Following residual test and
diagnostic plot assessments, the assumption of multiple
regression model was selected.
The highest adjusted R-squared value, determined using
the stepwise technique, was the statistical test applied to
choose the best model.
Ethics and regulatory approval
The study was carried out in compliance with the require-
ments established by the Spanish Agency of Medicines and
Medical Products (in Spanish: Agencia Española de Medi-
camentos y Productos Sanitarios, or AEMPS). AEMPS
classified the study as an Observational Post-Authorization
Study—Other Design and therefore, it only needed to be
approved by a single ethics committee.
All patients provided written informed consent to parti-
cipate in the study (by parents or legal guardians). Mature
children (≥12 years) participating in the study were also
asked to provide written informed assent. The procedures
were carried out in accordance with the Declaration of
Helsinki and approved by an independent ethic committee
(Comité Ético de Investigación Clínica de Aragón, Spain).
Results
A total of 153 subjects were included, but 43 patients were
excluded from the analysis because they did not meet the
eligibility criteria (Fig. 1). Baseline characteristics (socio-
demographic and auxological data) may be observed in
Table 1.
Only one subject had medical history data: hypothyr-
oidism treated orally with levothyroxine. The educational
level of the father or the mother was available in 74 and
75 subjects, respectively. In 9.5 and 13.3% of the cases the
parent had completed secondary education or less. The
pretreatment HV (HV0) and height gain are shown in
Table 2.
All patients have completed 2 years of treatment.
Quantitative adherence was very high throughout the study
first and second year (Table 2). The adherence was >95% in
75.5 and 68.2% of patients during the first and second year,
respectively. In qualitative terms, the adherence was 93.6%
during the first year and 89% during the second year.
At the start of the GH treatment
The age at the start of the GH treatment was positively
correlated with pretreatment height (SDS) (r= 0.485, p <
0.0001) and weight SDS (r= 0.352, p < 0.001) and nega-
tively correlated with the pretreatment HV (r=−0.327, p <
0.0001), CA/BA rate (r=−0.366, p < 0.0001), and Δ
HSDS (r=−0.370, p < 0.0001).
First year of rhGH treatment
During the first year, mean adherence was 95.6 ± 5.73%
(66–100%). GHD vs. SGA did not make a difference to
Fig. 1 Flow chart of the study
population selection
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adherence. At the end of the first year of treatment, the
absolute increment of HV was 4.42 SDS (SDS; HV0:
−2.04, HV in the first year (HV1): 2.38) (Table 2; Fig. 2).
The Δ HSDS was 0.57 SDS (21.1% increase) (Table 2;
Fig. 2).
CA/BA ratio was not different between baseline and after
the first year of treatment (Table 2).
The height SDS observed at the rhGH onset showed a
negative correlation with the dose of rhGH (r=−0.235,
p= 0.014). On the other hand, it had a positive association
with the height SDS (r= 0.795, p < 0.0001), weight SDS
(r= 0.371, p < 0.0001), and height prognosis (r= 0.258,
p= 0.027) after 1 year of treatment.
Adherence during the first year was better in younger
patients (both at the start of the rhGH treatment [r=−0.24,
p= 0.009] and at year 1 [r=−0.25, p= 0.008]), and also
in those patients with lower HV0 (SDS) (r=−0.230, p=
0.017) and higher HV1 (cm/year, r= 0.33, p= 0.01 and
SDS, r= 0.26, p= 0.006). Patients with better adherence
consistently, showed higher HV1-HV0 (r= 0.182, p=
0.04). The lower the HV0 (SDS), the greater the variation in
HV (HV0-HV1) (r=−0.499), p= <0.001.
Height gain (SDS) (r= 0.26, p= 0.006) during the first
year and parents´ educational level (mother: r= 0.21, p=
0.04; and father, r= 0.031, p= 0.006) showed a positive
correlation with the adherence during the first year.
Analyzing the good response factors in the first year,
there were no differences in the adherence (mean) in the
subgroups of patients with either height gain >0.3 SDS or
>0.5 SDS, or with HV > 1SDS or Δ HV > 3 cm/year during
the first year (Table 3). However, among patients with
adherence > 90%, the frequency of HV > 1 SD was higher
(p= 0.025).
Second year of rhGH treatment
Adherence during the second year of treatment was still
high (93.6; 68–100%). GHD vs. SGA did not make a dif-
ference to adherence. The group with optimal adherence
(Table 4) showed higher HV in the second year (HV2) (cm/
year). Both groups (adherence ≥85 and <85%) are similar in
terms of pubertal development.
At the end of the second year of treatment, the absolute
increase of HV from the rhGH onset was 3.94 SDS (Table 2;
Fig. 2). Total height gain was 0.99 SDS (a 37.4% increase)
(Table 2; Fig. 2).
Height and weight gain SDS between the first and second
year were 0.43 and 0.2 SD, respectively (Table 2; Fig. 2)
Table 1 Patients’ baseline characteristics (n= 110)
Overall (n= 110) GHD (n= 76) SGA (n= 34)
Gender—male, n (%) 57 (51.8) 39 (51.3) 18 (52.9)
Age, mean, years ± SD 8.5 ± 3.8 8.9 ± 3.6 6.5 ± 3.9
Range (years) (min–max) 1.3 –15.3 15.3 1.3 –15.3 4.2 –10.6
Tanner stage, n (%)
I 91 (82.7) 61 (80.3) 30 (88.3)
II 15 (13.6) 11 (14.5) 4 (11.7)
III 2 (1.8) 2 (2.6)
IV 1 (0.9) 1 (1.3)
V 1 (0.9) 1 (1.3)
Mean SD Min. Max. Mean SD Min. Max. Mean SD Min. Max.
Father height, cm 171.4 6.21 159.2 190.0 171.4 5.5 161.0 190.0 171.3 7.1 159.2 188.0
SDS −0.9 1.0 −2.8 2.0 −0.9 0.8 −2.6 2.0 −0.9 1.1 −2.8 1.7
Mother height, cm 157.4 5.8 135.8 173.7 157.1 4.9 139.0 173.7 157.7 6.8 135.8 170.0
SDS −1.1 1.0 −4.7 1.6 −1.1 0.8 −4.2 1.6 −1.1 1.1 −4.7 1.0
Target height, SDS −1.0 0.7 −2.9 1.4 −1.0 0.7 −2.8 1.1 −1.0 0.8 −2.9 1.4
Men, cm 169.9 6.4 164.1 179.0 170.5 5.4 164.4 179.0 169.5 6.0 164.1 178.8
Women, cm 158.8 5.9 147.4 172.5 158.5 5.8 147.7 172.5 159.3 5.5 147.4 171.9
Gestational age 38.4 2.8 27.0 42.0 38.8 2.4 31.0 41.0 37.8 3.1 27.0 42.0
Weight at birth,kg 2.6 0.7 0.57 3.8 2.8 0.5 1.2 3.8 2.2 0.6 0.57 3.5
SDS −1.2 1.0 −3.54 1.4 −0.6 0.8 −1.8 1.4 −2.0 0.8 −3.54 0.1
Size at birth, cm 46.3 3.9 28.0 52.0 48 2.7 39.0 52.0 44.1 4.0 28.0 49.0
SDS −1.4 1.2 −4.8 1.5 −0.5 0.6 −1.7 1.5 −2.5 0.8 −4.8 −0.2
GH peak upon stimulation, ng/ml 5.3 2.5 0.7
GH growth hormone, GDH GH deficiency, SD standard deviation, SDS SD score, SGA small for gestational age
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Table 2 Auxological variables along the study period
Basal (At start rhGH) At year 1 At year 2
n= 110 Mean SD Min. Max. Mean SD Min. Max. Mean SD Min. Max.
All patients
Years 8.5 3.8 1.3 15.3 9.5 3.8 2.2 16.2 10.5 3.8 3.2 17.2
rhGH dose, mg/kg/day 0.03 0.01 0.02 0.05 0.03 0.00 0.02 0.05 0.03 0.01 0.02 0.06
Weight, SDS −1.6 0.6 −3.4 −0.2 −1.3 0.5 −2.5 0.7 −1.1 0.6 −2.2 0.9
Height, SDS −2.6 0.5 −4.4 −1.6 −2.1 0.6 −3.8 −0.9 −1.7 0.6 −3.5 −0.1
Height velocity, cm/year 4.5 1.1 1.9 7.1 8.6 1.7 3.4 14.0 7.4 1.6 0.7 11.6
SDS −2.0 0.9 −4.7 −0.8 2.4 1.7 −2.0 10.7 1.9 1.8 −1.3 8.5
Height gain, SDS −0.2 0.3 −2.0 0.8 0.6 0.3 −0.2 2.0 0.4 0.3 −0.3 1.6
Bone age, years 7.2 3.7 1.0 13.5 8.4 3.7 1.5 14.5 9.6 3.7 3.5 15.7
CA/BA 1.2 0.2 0.9 2.1 1.2 0.2 0.9 1.7 1.1 0.11 0.88 1.5
Height prognosis, mean, cm
Men (n= 57) 162.4 7.5 158.2 184.1 165.1 7.7 161.2 188.1 166.8 7.2 163.7 195.7
Woman (n= 53) 148.3 6.6 140.3 155.8 152.5 6.5 143 163.2 154.8 6.8 142 166.1
IGF-I, ng/ml 133.5 84.6 5.0 381.8 310.7 172.9 48.1 808.3 332.5 174.3 42.7 849.4
IGF-BP3, mcg/ml 3.6 1.2 0.6 6.3 5.2 1.3 2.2 8.6 5.7 1.6 2.5 9.4
Adherence, % NA NA NA NA 95.6 5.7 66.0 100.0 94.0 7.6 68.0 100.0
IoR NA NA NA NA −0.1 1.3 −2.9 3.5 0.2 1.2 −3.9 3.9
n= 76
GHD
Age, years 8.9 3.6 1.3 15.3 9.9 3.4 2.2 16.2 10.9 3.7 3.2 17.2
rhGH dose, mg/kg/day 0.03 0.02 0.02 0.03 0.03 0.02 0.02 0.04 0.03 0.02 0.02 0.04
Weight, SDS −1.8 0.7 −2.9 −0.2 −1.2 0.5 −2.4 0.7 −1.1 0.6 −1.7 0.9
Height, SDS −2.4 0.4 −3.2 −1.6 −1.9 0.6 −2.9 −0.9 −1.5 0.6 −2.5 −0.1
Height velocity, cm/year 4.6 1.1 1.9 7.1 8.8 1.7 3.4 14.0 7.5 1.6 0.7 11.6
SDS −2.0 0.9 −4.7 −0.8 2.5 1.7 −2.0 10.7 1.9 1.8 −1.3 8.5
Height gain, SDS −0.2 0.3 −2.0 0.8 0.6 0.3 −0.2 2.0 0.4 0.3 −0.3 1.6
Bone age, years 7.4 3.5 1.0 13.5 8.4 3.7 1.5 14.5 9.5 3.7 3.5 15.7
CA/BA 1.2 0.2 0.9 2.1 1.2 0.2 0.9 1.7 1.1 0.11 0.9 1.5
Height prognosis, mean, cm
Men (n= 39) 161.5 7.7 158.2 174.1 164.2 7.3 161.2 176.1 165.8 7.2 163.7 179.7
Woman (n= 37) 148.2 6.6 140.3 154.5 152.4 5.4 143 159.3 154.7 6.8 142 165.7
IGF-I, ng/ml 129.4 81.2 5.0 381.8 301.2 199.9 48.1 808.3 342.7 224.3 42.7 849.4
IGF-BP3, mcg/ml 3.5 1.6 0.6 5.3 5.1 1.3 2.2 8.6 5.7 1.6 2.5 9.4
Adherence, % NA NA NA NA 95.7 5.7 66.0 100.0 94.0 7.6 68.0 100.0
IoR NA NA NA NA −0.1 1.3 −2.7 3.5 0.2 1.2 −3.9 3.9
n= 34
SGA
Age, years 6.5 3.9 4.2 10.6 7.5 3.8 5.2 11.6 8.5 3.6 6.2 12.6
rhGH dose, mg/kg/day 0.03 0.02 0.03 0.05 0.03 0.02 0.03 0.05 0.03 0.02 0.02 0.06
Weight, SDS −1.5 0.6 −3.4 −1.2 −1.3 0.5 −2.5 −0.2 −1.1 0.6 −2.2 0.4
Height, SDS −3.0 0.6 −4.4 −2.0 −2.4 0.7 −3.8 −1.1 −1.9 0.5 −3.5 −0.7
Height velocity, cm/year 4.4 1.0 3.1 5.4 8.5 1.7 5.4 10.4 7.4 1.6 6.1 9.6
SDS −1.9 0.9 −2.9 −0.9 2.3 1.7 −1.8 8.1 2.0 1.8 −0.5 6.5
Height gain, SDS −0.2 0.3 −2.0 0.8 0.6 0.3 0.0 1.9 0.4 0.3 0.0 1.5
Bone age, years 5.1 2.7 3.0 9.5 6.3 3.1 4.0 10.5 7.4 3.5 5.0 11.5
CA/BA 1.3 0.2 0.8 2.1 1.2 0.2 0.9 1.6 1.11 0.11 0.88 1.4
Height prognosis, mean, cm
Men (n= 18) 164.1 7.2 159.1 184.1 166.8 7.9 161.9 188.1 167.4 7.4 163.7 195.7
Woman (n= 16) 148.5 6.6 141.3 155.8 152.5 6.5 143.4 163.2 154.8 6.8 142.6 166.1
IGF-I, ng/ml 136.8 85.5 75 352.3 322.9 166.5 137.5 522.6 327.3 144.3 150.7 559.4
IGF-BP3, mcg/ml 3.6 1.1 1.6 6.3 5.2 1.1 2.2 6.6 5.7 1.5 2.5 7.1
Adherence, % NA NA NA NA 95.6 5.7 68.0 100.0 94.1 7.6 69.0 100.0
IoR NA NA NA NA −0.1 1.2 −2.9 3.1 0.2 1.3 −3.5 3.7
BA bone age, CA chronological age, GHD growth hormone deficiency, IGF-1 insulin-like growth factor-1, IGF-BP3 IGF binding protein-3, IoR
index of responsiveness, Max. maximum, Min. minimum, rhGH recombinant human growth hormone, SD standard deviation, SDS standard
deviation score, SGA small for gestational age
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The rhGH dose in the second year was higher in those
patients who had lower values of IoR1 (r=−0.423, p=
0.000), height SDS (r=−0.397, p= 0.000), HV SDS (r=
−0.218, p= 0.022), and HV1-HV0 (r=−0.211, p=
0.027) at year 1.
Height SDS at year 2 has a positive association with the
height SDS at year 1 (r= 0.887, p= 0.000), the IoR1 (r=
0581, p= 0.000), and the IoR2 (r= 0201, p= 0.035).
Patients with the highest IoR2 showed the best adherence
during the first and second year (r= 0.246, p= 0.01, and
r= 0.298, p= 0.002, respectively).
Adherence during the second year was higher among
younger children (both at the beginning and at year 2: r=
−0.28, p= 0.00, and r=−0.287, p= <0.01, respectively)
and among children with better adherence in the first year
(r= 0.836, p= <0.001). In addition, adherence showed a
direct correlation with HV1-HV0 (r= 0.201, p= 0.035)
and HV2 (r= 0.34, p= 0.00), as well as with the parents'
educational level (mother: r= 0.24, p= 0.03; and father,
r= 0.35, p= 0.00).
Height velocity after 2 years
Both in SGA and GHD children, HV (cm/year and SDS)
was higher in those patients with a higher adherence per-
centage (p= 0.03).
At year 2, HV was higher in those patients with adher-
ence >85 vs. <85% (7.6 ± 1.61 vs. 6.1 ± 1.34 cm/year, p=
0.001).
A decline of 0.6 cm/year in HV was observed for every
10% decrease in adherence in SGA children. For GHD
children, the decrease observed was 1.1 cm/year.
The percentage of adherence (%) and the Tanner stage
reached an adjusted R squared of 0.263, and these factors
consequently explain 26.3% of the variability of HV. When
this model was used for only GHD children, the adjusted R
squared increased to 0.334 and explain 33.4%. This model
explains 38.8% in SGA patients.
Height gain after 2 years
The height gain after 2 years of treatment was greater in
those patients with a higher adherence (%). For every 10%
decrease in adherence, a decline of 1.8 cm was observed.
Subjects with a higher dose of rhGH show greater height
gain after 2 years of treatment. Starting the treatment before
the onset of puberty was also associated with a greater
height gain of 2.5 cm.
The best fit model for the whole sample to predict height
gain (cm) reached an adjusted R squared of 0.388 and was
made up with the following independent variables: pre-
treatment HV, Tanner stage, percentage of adherence to the
rhGH, baseline BA, and gestational age.
In the case of children with GHD, the best fit model to
predict the height gain in cm reached an adjusted R-squared
of 0.489 and was made up with the following factors:
percentage of adherence, the Tanner stage, the baseline HV,
the dose of rhGH and whether the treatment was initiated
before or after puberty.
Nothing found for SGA children in this model.
Safety
A total of 110 subjects were assessed. There was only one
adverse event (AE) in one patient (0.9%)—one AE each: an
Osgood-Schlater disease. It was considered as unlikely
related to the treatment. No serious AEs or deaths have been
reported.
Discussion
Adherence to GH treatment is an extremely significant
determinant of its success [24, 25]. In our study of rhGH-
naïve children treated with GH (Easypod™ electronic
device with Connect platform) (n= 110), a 10% reduction
in adherence during the first 2 years was correlated with a
decrease of 1.1 cm/year in HV.
Overall, patients reached a good mean level of adherence
after only 1 year of rhGH treatment (95.64%), and
decreased slightly after 2 years (93.98%). These values are
very similar to the mean adherence rate observed in the
Spanish cohort (n= 238) from the ECOS study [8], which
showed 95.3% adherence at year 1 and 93.7% at year 2.
We observed almost the same percentages of adherence
in SGA and GDH population at 1 year (95.6% and 95.7%,
respectively) and 2 years (94.1% and 94.0%, respectively).
Fig. 2 Weight, height, and height velocity (SDS) variation during
rhGH treatment
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However, in the Spanish cohort of the ECOS study the
adherence at first year was higher in the SGA vs. GHD
patients (97.4% vs. 93.9%, respectively). In that study, the
decrease in the adherence observed at 2 years was greater in
the SGA patients; the percentages at that time were of 93.1
and 93.8% in SGA and GHD and patients, respectively.
These results confirm that there is high adherence in the
Spanish population, with higher values of adherence after 1
and 2 years than those observed in the overall population
(n= 608; excluding Spanish patients) and in the Italian
cohort (n= 73) from the ECOS study: 84.30% and 81.41%
[24] and 88.5% and 86.6% [26], respectively.
Despite the differences observed, all results showed that
adherence decreased with increasing treatment duration,
unlike what is observed in the Spanish cohort of the ECOS
study in which the duration of treatment did not showed
significant differences on treatment adherence
Notwithstanding the decrease in adherence after the
second year, the high percentage of adherence remained
consistently high throughout the treatment in those
patients with better responses (i.e., higher HV). A higher
percentage of HV > 1SDS was observed with adherence
>90% during the first year and adherence >85% during
the second year. In the Spanish ECOS study, height
Table 3 Adherence and measurements of efficacy in different subgroups of patients based on the results reached during the first year of rhGH
treatment
Height gain > 0.3 SD Height gain > 0.5 SD HV > 1 SD Δ HV > 3 cm/year
Yes n= 95 No n= 15 Yes n= 59 No n= 51 Yes n= 90 No n= 20 Yes n= 78 No n= 32
Adherence %
Mean 95.92 93.87 95.86 95.37 96.03 93.85 95.15 94.32
SD 5.6 6.09 6.25 5.12 5.40 6.92 4.96 7.23
SE mean 0.58 1.57 0.81 0.72 0.57 1.55 0.56 1,28
No difference No difference No difference No difference
Height SDS
Mean −2.02 −2.47 −1.89 −2.31 −2.01 −2.42 −1.93 −2.45
SD 0.56 0.54 0.55 0.52 0.54 0.61 0.50 0.57
SE mean 0.06 0.14 0.07 0.07 0.06 0.14 0.06 0.10
p= 0.005 p < 0.0100 p= 0.003 p < 0.0100
HV SDS
Mean 2.61 0.93 2.97 1.69 2.83 0.34 2.87 1.17
SD 1.73 0.77 1.80 1.38 1.56 0.69 1.71 1.06
SE mean 0.18 0.20 0.23 0.19 0.16 0.15 0.19 0.19
p < 0.0100 p < 0.0100 p < 0.0100 p < 0.0100
Δ HSDS, SDS
Mean 0.65 0.14 0.79 0.32 0.63 0.35 0.63 0.44
SD 0.29 0.14 0.28 0.15 0.32 0.26 0.34 0.24
SE mean 0.03 0.04 0.04 0.02 0.03 0.06 0.04 0.04
p < 0.0100 p < 0.0100 p < 0.0100 p= 0.005
HV1-HV0
Mean 4.29 2.49 4.49 2.52 4.40 2.45 4.99 1.73
SD 1.91 1.99 1.94 1.99 1.87 1.91 1.49 0.97
SE mean 0.20 0.51 0.25 0.28 0.20 0.43 0.17 0.17
p= 0.001 p= 0.011 p < 0.0100 p < 0.0100
IoR
Mean 0.04 −0.89 0.24 −0.45 0.15 −1.13 0.42 −1.31
SD 1.30 1.09 1.24 1.24 1.22 1.16 1.13 0.78
SE mean 0.13 0.28 0.16 0.18 0.13 0.26 0.13 0.14
p= 0.009 p= 0.005 p < 0.0100 p < 0.0100
HV height velocity, HV0 basal HV, HV1 HV at year 1, IoR1 index of responsiveness at year 1, rhGH recombinant human growth hormone, SD
standard deviation, SDS standard deviation score, SE standard error, Δ HSDS change in height SDS
Endocrine
(SDS) was also higher with adherence >85% after 3 years
of treatment [8].
In qualitative terms, adherence is considered “optimal”
when it is 85% or higher, and “suboptimal” if it is lower
than 85% (this threshold corresponds to adherence 6 out of
7 days). When adherence is considered in these terms, the
only correlation that is statistically significant is in relation
to the HV (expressed in cm/year, but not in SDS) in the
second year of treatment. This seems to indicate that, within
this sample of highly compliant subjects, the prespecified
threshold was not sensitive enough.
Nonadherence to rhGH treatment impacts growth
response [27]. Consistently, and in concordance with the
results of the ECOS study [8, 24], patients with a higher
adherence rate during 2 years showed higher HV (cm/year
and SDS), and therefore greater height gain (SDS). This
was despite the little variation in adherence at the high
extreme (above 90%).
In the first year of GH treatment, patients showed a
marked improvement in all of the main auxological vari-
ables that were assessed: HV and height gain. The rhGH
dose in the second year was higher in those patients who
had lower values of IoR1, height SDS, HV SDS, and HV1-
HV0 at year 1; perhaps it reflects proactive management
applied in these patients group based on IoR and adherence.
Our results showed that at least 2 years of rhGH treat-
ment are required to accelerate the increase in BA and to
observe a normalization of the BA in relation to CA. This
finding was previously observed in a randomized controlled
study using a similar rhGH dosage during 1 year [28]; after
the first year there was no difference in BA between
untreated and treated children. Furthermore, a recent ana-
lysis of data regarding prepubertal children with idiopathic
GH deficiency and idiopathic short stature treated with
rhGH over 3 years, also showed significant BA-CA changes
in the second year of treatment [29].
When considering the information presented above, it
becomes apparent that the importance of adherence in the
second year of treatment must be assessed and demon-
strated, because that’s when it starts to decrease. In cases
where adherence shows insufficient variation (as is sus-
pected with the use of electronic administering devices, and
when prescriptions are more recent), the assessment
becomes even more complex, further demonstrating the
need for adherence to be explored and examined [9].
In addition to the duration of treatment, other factors
showed a negative correlation with the adherence, such as
pretreatment HV. This could be justified by the fact that low
HV could raise awareness of the need for treatment and its
benefits, and thereby influence adherence [27]. Patients that
fit this category show the greatest improvement in HV
during the first year, which confirms the impact of adher-
ence on response to rhGH treatment [8].
Furthermore, during the first 2 years of rhGH treatment,
and as previously reported, adherence was inversely related
to chronological age at initiation of rhGH therapy [25]. This
might reflect the known fact that younger age as well as
adolescence are associated with a lower adherence to rhGH
treatment [2].
Our results also showed that the education level of the
parents was associated with a greater adherence during the
first and second year of rhGH treatment. Though this cor-
relation has been previously reported (either with regards to
the level of education of the mother, father or both) [30, 31],
the evidence has not been consistent [27].
The IoR1 and IoR2 allow for predicted positive
responses to GH treatment. The predictive value of these
parameters has been previously described. IoR1 has
shown differences between patients and has been used in
predictive models for near final adult height (nFAH) [22].
On the other hand, it is important to note that IoR2 has
been shown to be a strong association with adherence
during the first and second year [2], although it is not
used for its calculation.
One weakness of our study is its retrospective uncon-
trolled and observational nature. However, by using the
electronic device, EasypodTM, we have provided a precise
and objective measurement of adherence. This has
increased the amount of evidence regarding this available
device, yet very scarce.
Table 4 HV (cm/years) during the second year of rhGH treatment
based on adherence (optimal ≥ 85% vs. suboptimal < 85%)
HV Adherence ≥ 85% Adherence < 85% p
All patients
n 98 12
Mean 7.60 6.10 0.002
SD 1.61 1.34




Mean 7.69 6.2 0.002
SD 1.65 1.4




Mean 7.55 6.05 0.002
SD 1.11 1.3
Median 7.55 6.05 0.001
Min–max 6.1–9.6 4.5–8.4




In conclusion, measuring adherence to GH treatment is
essential in determining the effectiveness of the treatment
and assessing whether patients will be a good or poor
responders. In this study, adherence was very high during
the first 2 years of treatment. Although this observation
should be taken into account for the correct management of
patients, it might hinder our ability to accurately assess the
association between this variable and auxological outcomes.
Adherence showed a direct correlation with growth out-
comes throughout the treatment. It is important to recognize
that a 10% reduction in adherence may cause a decrease of
1.1 cm/year in HV. Furthermore, our results confirmed that
age and pretreatment HV, as well as the duration of the
treatment, showed a negative correlation with adherence,
whereas there was a positive association between adherence
and the education level of the parents. So, we think that it is
essential to use devices that allow an adequate assessment
of adherence for a better follow-up of patients.
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